Furthermore, TOP2A overexpression in HCC has been linked to earlier age of onset, shorter survival periods, and resistance to doxorubicin-based treatment, according to Wong et al., Therefore, there is an urgent need for new, more effective TOP2A-targeted chemotherapeutic drugs [48]. Here, TOP2A is linked to hepatocellular carcinoma.